Insider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) EVP Sells $64,422.12 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT) EVP Linda Burkly sold 11,886 shares of Editas Medicine stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $5.42, for a total value of $64,422.12. Following the transaction, the executive vice president now owns 73,136 shares of the company’s stock, valued at approximately $396,397.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Editas Medicine Stock Performance

EDIT opened at $5.65 on Monday. The stock has a market cap of $464.66 million, a price-to-earnings ratio of -2.69 and a beta of 2.01. The firm’s fifty day moving average is $5.26 and its 200 day moving average is $6.59. Editas Medicine, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $11.69.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.13). Editas Medicine had a negative return on equity of 47.34% and a negative net margin of 239.36%. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $11.14 million. During the same period last year, the company earned ($0.71) earnings per share. The firm’s revenue was down 88.9% on a year-over-year basis. On average, equities research analysts predict that Editas Medicine, Inc. will post -2.7 earnings per share for the current year.

Institutional Trading of Editas Medicine

A number of institutional investors have recently bought and sold shares of EDIT. Assenagon Asset Management S.A. lifted its stake in shares of Editas Medicine by 3.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 38,288 shares of the company’s stock worth $388,000 after acquiring an additional 1,384 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Editas Medicine by 401.9% during the 4th quarter. Russell Investments Group Ltd. now owns 5,190 shares of the company’s stock valued at $53,000 after buying an additional 4,156 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Editas Medicine by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,713 shares of the company’s stock valued at $117,000 after buying an additional 6,263 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Editas Medicine by 16.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,704 shares of the company’s stock worth $369,000 after acquiring an additional 7,174 shares in the last quarter. Finally, Headlands Technologies LLC increased its position in shares of Editas Medicine by 481.7% during the first quarter. Headlands Technologies LLC now owns 9,493 shares of the company’s stock worth $70,000 after acquiring an additional 7,861 shares during the period. 71.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

EDIT has been the subject of several analyst reports. Barclays reduced their price target on Editas Medicine from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. StockNews.com lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. Citigroup dropped their target price on shares of Editas Medicine from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Morgan Stanley upgraded shares of Editas Medicine from an “underweight” rating to an “equal weight” rating and set a $7.00 price objective for the company in a report on Thursday, May 9th. Finally, Evercore ISI dropped their price target on shares of Editas Medicine from $15.00 to $7.00 and set an “in-line” rating on the stock in a report on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.90.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.